MK2 inhibitors

A compound of Formula I,

• or a pharmaceutically acceptable salt thereof, wherein
• A is CH or N;
• Y is a bond, or —C(O)NH—;
• X is a bond, —CH2—, —CH2CH2—;
• V is —CH2—, O, C(O), —CHF—, or —CF2—, with the proviso that if V is O, X is —CH2CH2— and that if V is C(O), X is —CH2;
• W is a bond or —CH2—;
• R1 is hydrogen or F;
• R2 is a (1-12C)heteroaryl or (6-10C)aryl both optionally substituted with one or more groups independently selected from R4;
• R3 is a hydrogen;
• (3-6C)cycloalkyl;
• (1-6C)alkyl, —(CH2)mOR5;
• —(CH2)mNR5R6;
• or —C(O)CH2NR5R6;
• R4 is taken from halogen;
• OH;
• SH;
• nitrile, nitro, NH2;
• (3-6C)cycloalkyl, (3-6C)cycloalkoxy, (1-6C)alkoxy or (1-6C)alkyl, all optionally substituted with one or more halogen;
• phenoxy;
• —O(CH2)mOR5, —O(CH2)mNR7R8, —OC(O)R7 with the proviso that R7 is not hydrogen, —O(1-12C)heteroaryl), —S(1-6C)alkyl);
• —S(3-6C)cycloalkyl)-;
• NR7R8;
• —NR9(CH2)mOR7, —NR9(CH2)mNR7R8;
• (1-6C)alkylcarbonyl;
• (3-6C)cycloalkylcarbonyl;
• —C(O)NR7R8;
• —C(O)NR9(CH2)mNR7R8, —C(O)NR9(CH2)mOR7, —C(O)OR7, —SO2(1-6C)alkyl), —SO2(3-6C)cycloalkyl);
• —O(1-6C)alkyl)O— where the oxygens are attached to the (1-12C)heteroaryl or (6-10C)aryl ring on two neighboring carbons;
• phenyl or (1-12C)heteroaryl;
• R5 is hydrogen (3-6C)cycloalkyl;
• or (1-6C)alkyl;
• R6 is hydrogen;
• (3-6C)cycloalkyl;
• (1-6C)alkyl;
• or (1-6C)alkylcarbonyl;
• R7 is hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl;
• R8 is hydrogen;
• (3-6C)cycloalkyl;
• (1-6C)alkyl;
• or (1-6C)alkylcarbonyl;
• or
• R7 and R8 together with the nitrogen to which they are bonded in NR7R8 can form a 5-7-membered at least one nitrogen containing (4-6C)heterocyclyl ring which optionally contains one additional heteroatom selected from N, O or S;
• R9 is hydrogen;
• (1-6C)alkyl or (3-6)cycloalkyl;
• and
• m is 2 or 3.